이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Breath Gases, Gut Flora, and Immunity in Children With Constipation

2026년 8월 27일 업데이트: Ruijin Hospital

Correlation Study on End-expiratory NO, H2S, H2, CH4, Intestinal Flora and Immune Function in Children With Constipation

Constipation is a common problem in children that can affect their daily life, school performance, and social activities. Researchers have found that the bacteria living in our intestines (called "gut microbiome") may play an important role in constipation. However, we still do not fully understand exactly how these bacteria affect constipation in children.

This study aims to explore whether the gases children breathe out-including nitric oxide (NO), hydrogen sulfide (H₂S), hydrogen (H₂), and methane (CH₄)-can tell us something about the bacteria in their guts. By comparing children with constipation to healthy children, we hope to find out:

Whether the gases in their breath are different Whether the types of bacteria in their guts are different Whether there is a relationship between breath gases and gut bacteria If we find clear connections, this could lead to a simple, non-invasive breath test that doctors can use to understand a child's gut health without the need for more invasive procedures.

연구 개요

상태

모집하지 않고 적극적으로

상세 설명

Childhood functional constipation (FC) is a multifactorial syndrome with a global prevalence of approximately 9.5% among pediatric populations, accounting for up to 29% of functional gastrointestinal disorders. It significantly affects physical health, academic performance, and psychosocial development, with approximately 25% of affected children continuing to experience gastrointestinal symptoms into adulthood. While conventional factors such as diet, fluid intake, and psychological stress have been implicated, the precise pathophysiological mechanisms remain incompletely understood.

Emerging evidence highlights the critical role of the gut microbiome in regulating intestinal motility and visceral sensitivity through the microbiota-gut-brain axis. Microbial metabolites-including short-chain fatty acids (SCFAs), serotonin, bile acids, and gases (methane, hydrogen, hydrogen sulfide)-serve as key signaling molecules that influence enteric neurotransmission, smooth muscle contraction, and gastrointestinal transit time. Notably, hydrogen (H₂) and methane (CH₄) are exclusively of microbial origin (produced via anaerobic fermentation of carbohydrates by intestinal flora), while hydrogen sulfide (H₂S) is generated both endogenously and by sulfate-reducing bacteria. Nitric oxide (NO), though primarily endogenously produced, may also reflect intestinal inflammatory status and microbial metabolic activity.

The integration of breath gas analysis and metagenomic profiling offers a promising, non-invasive approach to elucidate host-microbe interactions in FC. However, systematic evaluations linking these four exhaled gases (NO, H₂S, H₂, CH₄) to the taxonomic and functional composition of the gut microbiome in constipated children remain scarce. This study is designed to bridge this knowledge gap, providing mechanistic insights and potentially establishing breath testing as a surrogate marker for gut dysbiosis in pediatric constipation.

연구 유형

관찰

등록 (추정된)

200

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, 중국, 200025
        • Ruijin Hospital

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 어린이

건강한 자원 봉사자를 받아들입니다

예

샘플링 방법

비확률 샘플

연구 인구

Children aged 6 to 14 years recruited from the outpatient clinic of the Department of Pediatrics at Ruijin Hospital (North Campus), Shanghai, China. The study population includes two groups: (1) children diagnosed with functional constipation according to Rome criteria, and (2) healthy children undergoing routine health check-ups with no chronic or acute digestive disorders. All participants must have no recent (within 4 weeks) exposure to antibiotics, probiotics, or medications affecting gastrointestinal motility. Informed consent is obtained from the legal guardian of each participant.

설명

Inclusion Criteria:

  • Children aged 6 to 14 years, male or female.
  • Legal guardian provides written informed consent.
  • No use of antibiotics, probiotics, lactulose, antacids, or gastrointestinal prokinetic agents within 4 weeks prior to enrollment.
  • For the constipation group: Clinical diagnosis of functional constipation according to Rome criteria, defined as meeting at least two of the following criteria for two consecutive months: (a) fewer than two bowel movements per week; (b) at least one episode of fecal incontinence per week; (c) history of massive fecal retention or posturing related to fecal retention; (d) history of painful or difficult defecation; (e) presence of a large fecal mass in the rectum; (f) passage of stools large enough to obstruct the toilet. Additionally, no enema or acute enteritis within 2 weeks prior to enrollment.
  • For the healthy control group: No chronic digestive diseases or acute illnesses; no enema or acute enteritis within 2 weeks prior to enrollment.

Exclusion Criteria:

  • Use of antibiotics, probiotics, lactulose, antacids, or gastrointestinal prokinetic agents within 4 weeks prior to enrollment (if not already excluded at screening).
  • Clinically significant abnormalities in liver, kidney, neurological, respiratory, or coagulation function as determined by the investigator.
  • Unstable vital signs.
  • Presence of other underlying systemic diseases (e.g., metabolic, endocrine, or organic gastrointestinal disorders).
  • Any other condition that, in the investigator's opinion, makes the participant unsuitable for enrollment.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

코호트 및 개입

그룹/코호트
Constipation Group
Children aged 6 to 14 years diagnosed with functional constipation according to Rome criteria (at least two of the following for two consecutive months: fewer than two bowel movements per week; at least one episode of fecal incontinence per week; history of massive fecal retention or posturing related to fecal retention; history of painful or difficult defecation; presence of a large fecal mass in the rectum; passage of stools large enough to obstruct the toilet). Participants have not used antibiotics, probiotics, lactulose, antacids, or prokinetic agents within 4 weeks prior to enrollment, and have not received enema or had acute enteritis within 2 weeks. Intervention: Non-interventional; participants undergo a one-time breath test (end-expiratory NO, H₂S, H₂, CH₄), stool collection (within 2 days), and blood draw (2 mL).
Control Group
Healthy children aged 6 to 14 years with no chronic digestive diseases or acute illnesses, recruited from routine health check-up visits. Participants have not used antibiotics, probiotics, lactulose, antacids, or prokinetic agents within 4 weeks prior to enrollment. Intervention: Non-interventional; participants undergo a one-time breath test (end-expiratory NO, H₂S, H₂, CH₄), stool collection (within 2 days), and blood draw (2 mL).

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
End-expiratory concentrations and peak values of H2
기간: Measured at baseline (single time point) after an overnight fast, during a single methane-hydrogen breath test session.
Comparison of the fasting end-expiratory concentrations (ppm) and peak values of hydrogen (H2) between children with functional constipation and healthy controls. Breath samples are collected during a single morning session after an overnight fast using a validated portable breath analyzer.
Measured at baseline (single time point) after an overnight fast, during a single methane-hydrogen breath test session.

2차 결과 측정

결과 측정
측정값 설명
기간
End-expiratory concentrations and peak values of H2S
기간: Measured at baseline (single time point) after an overnight fast, during a single methane-hydrogen breath test session.
Comparison of the fasting end-expiratory concentrations (ppm) and peak values of hydrogen sulfide (H2S) between children with functional constipation and healthy controls. Breath samples are collected during a single morning session after an overnight fast using a validated portable breath analyzer.
Measured at baseline (single time point) after an overnight fast, during a single methane-hydrogen breath test session.
End-expiratory concentration and peak value of methane (CH₄)
기간: Measured at baseline (single time point) after an overnight fast, during a single methane-hydrogen breath test session.
Comparison of fasting end-expiratory CH₄ concentration (ppm) and peak values between children with functional constipation and healthy controls. CH₄ is exclusively produced by methanogenic archaea in the gut and is not metabolized by mammalian cells. Elevated CH₄ levels (e.g., ≥10 ppm) are associated with prolonged colonic transit time and increased constipation severity. The analysis will compare intergroup differences in both baseline concentration and maximum peak values during the breath test.
Measured at baseline (single time point) after an overnight fast, during a single methane-hydrogen breath test session.
End-expiratory concentration and peak value of nitric oxide (NO)
기간: Measured at baseline (single time point) after an overnight fast, during a single methane-hydrogen breath test session.
Comparison of fasting end-expiratory NO concentration (ppb) and peak values between children with functional constipation and healthy controls. End-expiratory NO reflects systemic and intestinal inflammatory status. Alterations in NO levels may indicate mucosal barrier dysfunction or low-grade inflammation associated with constipation. The analysis will compare intergroup differences in both baseline concentration and maximum peak values.
Measured at baseline (single time point) after an overnight fast, during a single methane-hydrogen breath test session.

기타 결과 측정

결과 측정
측정값 설명
기간
Fecal metabolomic profiles
기간: Within 2 days after the breath test (baseline)
Identification and comparison of untargeted fecal metabolomic profiles via LC-MS/MS between constipated children and healthy controls. Differential metabolites and enriched KEGG metabolic pathways will be identified.
Within 2 days after the breath test (baseline)
serum gastrointestinal hormone levels
기간: At the single study visit (baseline)
Comparison of serum levels of gastrointestinal hormones (e.g., motilin) and routine blood parameters between the two groups. Blood samples (2 mL) are drawn at enrollment and processed via ELISA and automated hematology analyzers.
At the single study visit (baseline)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 1월 1일

기본 완료 (추정된)

2027년 12월 31일

연구 완료 (추정된)

2027년 12월 31일

연구 등록 날짜

최초 제출

2026년 8월 17일

QC 기준을 충족하는 최초 제출

2026년 8월 27일

처음 게시됨 (실제)

2026년 9월 1일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 1일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 8월 27일

마지막으로 확인됨

2026년 8월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • C001

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

IPD 계획 설명

Individual participant data (IPD) will not be shared publicly due to the following reasons: (1) This is a single-center observational study with a relatively small sample size (N=200), and the data are collected specifically for the exploratory objectives of this protocol; (2) The study involves pediatric participants (ages 6-14), and the informed consent form, approved by the institutional ethics committee, does not include provisions for sharing individual-level data with external investigators; (3) The data include sensitive genomic (metagenomic sequencing) and metabolomic profiles, which may carry re-identification risks; (4) The research team lacks the infrastructure and funding to support data anonymization, transfer, and external curation at this time. Summary-level results will be disseminated through peer-reviewed publications and conference presentations.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다